- Date 27 May 2020
Nuformix plc (LSE:NFX) (“Nuformix” or “the Company”), the pharmaceutical development company focused on unlocking the therapeutic potential and value of known drugs and VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system “CNS” diseases and disorders with high unmet need, today announced their agreement to develop novel cocrystal-based formulations of VistaGen’s CNS product candidates.
You might also be interested in these articles
Cambridge Science Park Director Jane Hutchins is now a Board Director of UKSPA (United Kingdom Science Park Association).
Thu 16 Jan 2025
Cambridge Science Park Director Jane Hutchins is now a Board Director of UKSPA (United Kingdom Science Park Association).
Thu 16 Jan 2025
Cambridge Science Centre Welcomes Rebecca Porter as New CEO
Wed 11 Dec 2024
